ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2019
Redox-Responsive Dual Drug Delivery Nanosystem Suppresses Cancer Repopulation by Abrogating Doxorubicin-Promoted Cancer Stemness, Metastasis, and Drug Resistance.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 74 citations in OpenAlex.
- Plasticity of Non-Apoptotic Residual Tumor Cells After Neoadjuvant Immunochemotherapy: Epigenetic and Microenvironmental Determinants.Biomolecules · 2026Review
- Biomaterial-based strategies for postoperative residual tumors: From margin clearance to immune control and tissue repair.Materials today. Bio · 2026Review
- Bioactive polymers as stimulus-responsive anti-metastatic combination agents to treat pancreatic cancer.Biomaterials · 2025Article
- Nanotherapeutic strategies exploiting biological traits of cancer stem cells.Bioactive materials · 2025Review
- Cyclodextrins as Multifunctional Platforms in Drug Delivery and Beyond: Structural Features, Functional Applications, and Future Trends.Molecules (Basel, Switzerland) · 2025Review
- Tumor microenvironment targeted nano-drug delivery systems for multidrug resistant tumor therapy.Theranostics · 2025Review
- Personalized nanovaccines for treating solid cancer metastases.Journal of hematology & oncology · 2024Review
- Advances, limitations and perspectives in the use of celecoxib-loaded nanocarriers in therapeutics of cancer.Discover nano · 2024Review
- Review
- Intelligent Systems based on Cyclodextrins for the Treatment of Breast Cancer.Current pharmaceutical design · 2024Review
- An infection-microenvironment-targeted and responsive peptide-drug nanosystem for sepsis emergency by suppressing infection and inflammation.Asian journal of pharmaceutical sciences · 2023Article
- Nanomedicine strategies to counteract cancer stemness and chemoresistance.Exploration of targeted anti-tumor therapy · 2023Review
- Doxorubicin-Induced Platelet Activation and Clearance Relieved by Salvianolic Acid Compound: Novel Mechanism and Potential Therapy for Chemotherapy-Associated Thrombosis and Thrombocytopenia.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Multifunctional co-transport carriers based on cyclodextrin assembly for cancer synergistic therapy.Theranostics · 2022Review
- Self-assembled ternary hybrid nanodrugs for overcoming tumor resistance and metastasis.Acta pharmaceutica Sinica. B · 2021Article
- Biodegradable and Dual-Responsive Polypeptide-Shelled Cyclodextrin-Containers for Intracellular Delivery of Membrane-Impermeable Cargo.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021Article
- Redox-Responsive Mesoporous Silica Nanoparticles for Cancer Treatment: Recent Updates.Nanomaterials (Basel, Switzerland) · 2021Review
- Emerging nanomedicine-based therapeutics for hematogenous metastatic cascade inhibition: Interfering with the crosstalk between "seed and soil".Acta pharmaceutica Sinica. B · 2021Review
- An Update on Mesoporous Silica Nanoparticle Applications in Nanomedicine.Pharmaceutics · 2021Review
- Nanoplatform based on GSH-responsive mesoporous silica nanoparticles for cancer therapy and mitochondrial targeted imaging.Mikrochimica acta · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chemotherapy is a major therapeutic option for cancer patients. However, its effectiveness is challenged by chemodrugs' intrinsic pathological interactions with residual cancer cells. While inducing cancer cell death, chemodrugs enhance cancer stemness, invasiveness, and drug resistance of remaining cancer cells through upregulating cyclooxygenase-2/prostaglandin-E2 (COX-2/PGE
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.